# A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)

> **NCT01010906** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Vaniprevir 300 mg
- **DRUG:** Vaniprevir 200 mg

## Key facts

- **NCT ID:** NCT01010906
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-01
- **Primary completion:** 2010-06-11
- **Final completion:** 2010-06-21
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010906, "A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01010906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*